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Cytochrome P450 3A4 and P-glycoprotein
mediate the interaction between an oral
erythromycin breath test and rifampin
Background: The intravenous 14C-erythromycin breath test (ERMBTIV) does not measure aggregate liver and
intestinal cytochrome P450 (CYP) 3A4 activity. Accordingly, we evaluated an oral stable-labeled (13C)
formulation of the test (ERMBToral) as an alternative CYP3A4 phenotyping probe.
Methods: After an overnight fast, 14 young healthy volunteers (5 women and 9 men) received the ERMBTIV
(0.07 mol, 3 Ci), followed by the ERMBToral (500 mg). The next morning, the CYP3A4 inhibitor
troleandomycin (500 mg) was given, and both ERMBTs were repeated. After at least 24 hours, the CYP3A4
and P-glycoprotein inducer rifampin (600 mg; INN, rifampicin) was given daily for 7 days, and both
ERMBTs were repeated 24 hours after the last dose of rifampin. Plasma samples were collected for 10 hours
with each administration of the ERMBToral, and erythromycin levels were measured by liquid chromatog-
raphy–mass spectrometry. Finally, the effect of troleandomycin on erythromycin transport was examined in
Caco-2 cell monolayers.
Results: Compared with baseline values, the median ERMBTIV and ERMBToral results and erythromycin
apparent oral clearance (CL/F) all significantly decreased, by at least 70%, with troleandomycin treatment
(P  .001 for each comparison). With rifampin treatment, the median ERMBTIV result and CL/F increased
2-fold (P < .01), but the median ERMBToral result was unchanged (P  .30). There were no rank-order
correlations between the ERMBTIV and ERMBToral results or between either ERMBT result and CL/F
within each treatment group (P> .07). In addition, troleandomycin had no effect on erythromycin transport
in Caco-2 cells (P > .20).
Conclusions: The ERMBToral was influenced by processes in addition to intestinal and hepatic CYP3A4
activity and therefore did not provide a straightforward measure of aggregate CYP3A4 phenotype. The
erythromycin-rifampin interaction cannot be attributed to CYP3A4 induction alone and probably also
reflected intestinal P-glycoprotein induction. (Clin Pharmacol Ther 2002;72:524-35.)
Mary F. Paine, PhD, David A. Wagner, PhD, Keith A. Hoffmaster, BS, and
Paul B. Watkins, MD Ann Arbor, Mich, Chapel Hill, NC, and Nashua, NH
The intravenous erythromycin breath test (ERMB-
TIV) was developed more than a decade ago as a simple
and relatively noninvasive index of cytochrome P450
(CYP) 3A4 activity in vivo.1 The theory behind this test
stems from the observation in human liver microsomes
that CYP3A4 is the major enzyme involved in the primary
metabolic pathway of erythromycin, N-demethylation.1
Following this common CYP-mediated oxidative reac-
tion, the cleaved methyl group, as formaldehyde, is further
enzymatically converted to bicarbonate, which then equil-
ibrates with alveolar carbon dioxide.2 Because the
ERMBTIV uses [14C-N-methyl]erythromycin, 14CO2 is
liberated in breath. (A complete scheme of the various
steps involved in the CYP3A4-mediated production of
14CO2 from [14C-N-methyl]erythromycin was recently
described by Rivory et al.3) By calculation of the rate of
appearance of 14CO2 in breath, as early as 20 minutes after
injection,4 an indirect but rapid measure of CYP3A4 ac-
tivity is obtained.
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The ERMBTIV has been shown to predict a signifi-
cant portion of the interindividual variation in the dis-
position of some CYP3A4 substrates, including the
immunosuppressant cyclosporine (INN, ciclosporin),5
the nonnucleoside reverse transcriptase inhibitor dela-
virdine6 and, most recently, the chemotherapeutic agent
docetaxel.7 In addition, the ERMBTIV appears to be
sensitive to the effects of CYP3A4 inducers, such as
glucocorticoids and rifampin (INN, rifampicin),1,8,9
and especially to a variety of CYP3A4 inhibitors. Ke-
toconazole, clarithromycin, amprenavir, delavirdine,
and troleandomycin have all been shown to reduce
average ERMBTIV results by at least 60% in compar-
ison with baseline values.1,6,10-12 These findings sug-
gest that this test could be particularly useful in the
prediction of drug-drug interactions in which CYP3A4
is a major determinant.
In addition to being highly expressed in the liver,
CYP3A4 is highly expressed in the small intestine.13
The ERMBTIV result would, therefore, appear to reflect
only hepatic CYP3A4 activity because intravenous ad-
ministration should avoid significant metabolism by the
gut. Indeed, the average rate at which 14CO2 was ex-
haled by patients with severe liver disease was just 16%
of that in subjects with normal liver function,14 and
14CO2 production was negligible during the anhepatic
phase of a liver transplant operation.15 Therefore, if the
goal were to assess aggregate intestinal and hepatic
CYP3A4 activity, the ERMBTIV alone would not suf-
fice. Accordingly, we developed an oral stable isotope
(13C)-labeled formulation of the ERMBT (ERMBToral).
We began our validation of this test by examining the
effects of a prototypical CYP3A4 inhibitor (troleando-
mycin) and inducer (rifampin) on the rate of 13CO2
production. This investigation further revealed that
mechanisms in addition to CYP3A4-mediated metabo-
lism govern the erythromycin-rifampin interaction.
MATERIAL AND METHODS
Materials and chemicals
Uncoated track-etched polyethylene terephthalate in-
serts and murine laminin were purchased from Collab-
orative Biochemical Products (Bedford, Mass). Dul-
becco’s modified Eagle medium with high glucose,
Hanks balanced salt solution, and nonessential amino
acids were purchased from Invitrogen (Carlsbad, Calif).
Fetal bovine serum was purchased from Hyclone (Lo-
gan, Utah). Gentamicin (in lieu of penicillin-
streptomycin), dl--tocopherol, sodium selenite, zinc
sulfate, unlabeled digoxin, unlabeled erythromycin,
troleandomycin, and oleandomycin were purchased
from Sigma Chemical Co (St Louis, Mo). [3H]Digoxin
(19 Ci/mmol) was purchased from New England Nu-
clear (Boston, Mass). [14C-N-methyl]erythromycin
(54.5 mCi/mmol) was purchased from Metabolic Solu-
tions, Inc (Nashua, NH). [13C2-N,N-methyl]erythro-
mycin was obtained from Cambridge Isotope Labora-
tories, Inc (Andover, Mass). Before use, the bulk ma-
terial was analyzed by high-resolution mass spectrom-
etry (to determine identity), combustion isotope ratio
mass spectrometry (to determine 13C enrichment), and
HPLC (to determine purity); weighed in 500-mg quan-
tities; and then placed into unit-dose capsules.
LY335979 [full chemical name, (2R-anti-5-{3-[4-(10,11-
difluoromethanodibenzo-suber-5-yl)piperazin-1-yl]-2-
hydroxypropoxy} quinoline trihydrochloride)], a selec-
tive P-glycoprotein inhibitor,16 was a gift from Eli Lilly
and Co (Indianapolis, Ind). All other chemicals and
reagents were of tissue culture or reagent grade when
appropriate.
Reproducibility of the ERMBToral
To evaluate the reproducibility of the ERMBToral, a
preliminary investigation was conducted in 15 healthy
nonsmoking volunteers who were maintained on their
usual diets. The test was administered to each subject
on 3 separate occasions—days 1, 2, and 8. On the
morning of each day, a single oral dose of [13C2-N,N-
methyl]erythromycin (500 mg, equivalent to 1.14
mmol erythromycin base), was given with 3 Maalox
(Novartis, East Hanover, NJ) tablets (to neutralize
stomach acid and minimize erythromycin degradation)
and 8 ounces of water. The subject was instructed to
exhale through a Quintron disposable modified
Haldane-Priestley tube (Milwaukee, Wis) that was con-
nected to a plastic bag. Breath samples were collected
into Exetainer breath storage tubes (Labco Ltd, High
Wycombe, United Kingdom) just before dose adminis-
tration and at 30-minute intervals for 3 hours thereafter.
Each breath sample was analyzed for 13CO2 content by
mass spectrometry (see “Analytic procedures”).
Human subject study
Subjects. A separate group of healthy nonsmoking
volunteers (5 women and 9 men; age range, 21-43
years; weight range, 47-83 kg) participated in the study.
Before enrollment, each subject had normal findings
after a routine physical examination and laboratory
tests that included hematologic testing, serum chemical
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testing, and urinalysis. In addition, none of the women
were of childbearing potential. No subject was taking
other medications, either prescription or nonprescrip-
tion, for at least 2 weeks before and during the study,
and no subject had known allergies to macrolide anti-
biotics or rifampin. All subjects were instructed to
refrain from consuming grapefruit-containing products
and alcoholic beverages beginning at least 2 days be-
fore and during the course of the study. The University
of Michigan Institutional Review Board approved the
study, and all subjects provided written informed con-
sent.
Study design. This study consisted of 3 phases, each
preceded by an overnight fast. On the morning of the
first phase (day 1), an indwelling heparin-lock catheter
was placed into an arm vein of each subject for blood
collection. The subject was then administered an intra-
venous dose of [14C-N-methyl]erythromycin (0.07
mol, 3 Ci) into the opposite arm. Subsequently, a
single oral dose of [13C2-N,N-methyl]erythromycin was
administered. Blood (5 mL) was collected just before
oral drug administration and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5,
4, 5, 6, 8, and 10 hours thereafter. Plasma was separated
from blood cells by centrifugation and was stored at
20°C, pending analysis for erythromycin. The second
phase began the following morning (day 2) when the
subject was given a single oral dose (500 mg) of trole-
andomycin (TAO; Pfizer Inc, New York, NY). Two
hours later and at the same times used for the previous
day’s tests, the ERMBTIV and ERMBToral were admin-
istered. Blood sample collections were repeated. Phase
3 began the next morning (day 3) or up to 7 days later
when the subject was given a single oral dose (600 mg)
of rifampin (Rifadin; Aventis Pharmaceuticals, Kansas
City, Mo). For the next 6 consecutive mornings, the
subject was given the same oral dose of rifampin. On
the day after the final rifampin dose, both ERMBTs and
blood sample collections were repeated. During all 3
phases, the subject was not allowed to eat until after the
4-hour blood sample was drawn.
Intravenous and oral erythromycin breath tests. For
the ERMBTIV, before and 20 minutes after injection,
each subject was instructed to exhale through a tube
into a scintillation vial that contained a CO2 trapping
solution (hyamine and ethanol) as described previous-
ly.1 Expired 14CO2 was measured by liquid scintillation
counting. Results are expressed as the percentage of
administered 14C exhaled during the first hour after
injection, as estimated by a single breath collection at
20 minutes.17 The ERMBToral was administered and
breath was collected during the ensuing 3 hours exactly
as described for the reproducibility study. Results are
expressed as the percentage of the dose exhaled as
13CO2 during the interval from 0 to 3 hours.
Analytic procedures
13CO2 in breath after ERMBToral administration.
The amount of 13CO2 in the breath storage tubes was
determined by use of a Europa Scientific 20/20 gas
isotope ratio mass spectrometer (Cincinnati, Ohio). The
ratio of 13CO2 to 12CO2 (mass 45 and 44, respectively)
was measured in each sample and compared with a
reference gas (5% CO2, balanced with 75% N2 and
20% O2). The reference gas was calibrated with inter-
national standards. The units of measurement were
atom percentage of 13C expired (APE) and were de-
fined by the following equation:
APE 13CO2/(13CO2 12CO2) 100%
Standards of carbon dioxide gas at 3 different levels
of APE were analyzed before and after each daily run
to assess instrument performance. The analytic preci-
sion of the instrument was 0.0001 APE. The APE
values from each breath sample were used to calculate
the percentage of the dose recovered during each time
interval. The area under the APE-versus-time curve for
each of the 0- to 1-, 1- to 2-, and 2- to 3-hour intervals
(AUCbreath) was calculated by use of the linear trape-
zoidal method. The percentage of the dose metabolized
during each 1-hour interval was calculated as the ratio
of the total amount of 13C recovered (in millimoles) in
that interval (13Cinterval) to the administered dose (1.14
mmol), for which 13Cinterval was calculated according to
the following equation:
13Cinterval (mmol) AUCbreath (h)
 CO2 production rate (mmol/min/m2 BSA)
 BSA (m2)  60 min/h
in which BSA is body surface area. The CO2 produc-
tion rate was assumed to be 5 mmol CO2/min/m2
BSA.18
Erythromycin in plasma after oral administration.
The concentration of erythromycin in plasma was de-
termined by use of HPLC with mass spectrometric
detection. Plasma (100 L) was spiked with 300 ng
oleandomycin as the internal standard. Samples were
mixed by vortex for approximately 10 seconds and then
centrifuged for 5 minutes at 14,000g. The supernatant
was recovered, and a 5-L aliquot was injected onto a
Hewlett Packard 1090 Series II liquid chromatography
system (Palo Alto, Calif) coupled to a Sciex API III
mass spectrometer (Thornhill, Ontario, Canada). Ana-
lytes were separated with a Phenomenex IB-SIL
C18-BD column (3 m, 3.3 cm  4.6 mm; Torrance,
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Calif). The mobile phase, consisting of methanol and
25-mmol/L ammonium acetate (76:24), was delivered
at a constant flow rate of 1 mL/min. The effluent flowed
directly into the electrospray ion source of the mass
spectrometer, which was operated in the selected ion
monitoring mode. The [MH] ions at mass-to-charge
ratios of 736.7 (13C2-erythromycin) and 688.7 (olean-
domycin) were monitored. A set of 8 nonzero calibra-
tion standards that ranged from 20 to 2000 ng/mL and
quality control samples at concentrations of 60, 800,
and 1700 ng/mL were run during each day of analysis.
The calibration curve was linear over the range studied,
with a correlation coefficient 0.995. Samples with
nominal concentrations above the highest calibration
standard were diluted and reanalyzed in a subsequent
batch. The interassay coefficients of variation for the
quality control samples were 10.9%, 3.8%, and 4.1%
for the low-, middle-, and high-quality control samples,
respectively. The accuracy of the assay ranged from
93% to 99% nominal of the known standard. The low
volume injected onto the liquid chromatography–mass
spectrometry system did not compromise the chroma-
tography or the ionization of the analytes for the dura-
tion of analysis.
Pharmacokinetic analysis
The pharmacokinetics of erythromycin after oral ad-
ministration were evaluated by use of noncompartmen-
tal methods. The terminal elimination rate constant (Z)
was determined by log-linear regression of at least the
last 3 data points from the plasma concentration–time
profile. The terminal elimination half-life (t1/2) was
calculated as ln2/Z. The area under the plasma con-
centration–time curve (AUC) was calculated by use of
the linear trapezoidal method and extrapolation to in-
finite time by dividing the last measured concentration
by Z. The apparent oral clearance (CL/F) was calcu-
lated as the ratio of dose to AUC. The maximum
plasma concentration (Cmax) and the time to reach Cmax
(tmax) were obtained by visual inspection of the con-
centration–time profile.
Evaluation of troleandomycin as an inhibitor of
erythromycin transport
Cell culture inserts were coated with the extracellular
matrix protein laminin (5 g/cm2), as described previ-
ously,19 onto which the Caco-2 cell clone P27.7,20
passage 33, was seeded at a density of approximately
5  105 cells/cm2. When confluence was achieved
(transepithelial electrical resistance values 250  
cm2), the cell monolayers were treated for 2 weeks with
differentiation medium (devoid of 1,25-
dihydroxyvitamin D3) as described previously.19,20 In-
cubation medium (serum-free differentiation medium)
was freshly prepared and kept at 37°C. LY335979,
troleandomycin, and unlabeled digoxin were dissolved
as 1000-fold concentrated solutions in dimethyl sulfox-
ide. [3H]-Digoxin was further diluted in absolute etha-
nol. Unlabeled erythromycin was dissolved as a 100-
fold concentrated solution in ethanol. The contents of 4
single-dose vials of [14C-N-methyl]erythromycin were
combined and concentrated (about 30-fold) under a
gentle stream of nitrogen to deliver 0.5 Ci of radio-
activity per culture insert while minimizing the final
concentration of ethanol.
Incubation medium was spiked either with drug(s) or
with vehicle (dimethyl sulfoxide or ethanol), or with
both, just before its addition to triplicate cultures. As a
“preincubation” step, incubation medium (1.5 mL) that
contained either troleandomycin, LY335979, or an ap-
propriate vehicle was added to the apical (luminal)
chamber of the insert, followed by an equal volume of
plain incubation medium to the basolateral chamber.
After 30 minutes at 37°C, apical and basolateral media
were removed and immediately replaced with the var-
ious combinations of erythromycin or digoxin and pre-
incubation compound or vehicle. Final concentrations
of troleandomycin, LY335979, dimethyl sulfoxide, and
ethanol were 30 mol/L, 0.5 mol/L, 0.1% (vol/vol),
and 1% (vol/vol), respectively. Under these conditions,
troleandomycin was at the limit of solubility.
To evaluate apical-to-basolateral (A3B) transloca-
tion of erythromycin across the cell monolayers, incu-
bation medium that contained [14C]erythromycin (10
mol/L, 0.5 Ci) and one of the preincubation com-
pounds (or vehicle) was added to the apical chamber,
followed by incubation medium plus an appropriate
vehicle to the basolateral chamber. To evaluate
basolateral-to-apical (B3A) translocation of erythro-
mycin, incubation medium that contained [14C]-
erythromycin was added to the basolateral chamber,
followed by incubation medium that contained one of
the preincubation compounds (or vehicle) to the apical
chamber. Samples (40 L) were collected from both
the apical and basolateral compartments of each insert
at 1, 2, 3, and 4 hours after the addition of [14C]eryth-
romycin. As a positive control for P-glycoprotein ac-
tivity, an identical experiment was performed with the
P-glycoprotein substrate [3H]digoxin (5 mol/L, 1
Ci). The medium collected from the apical and baso-
lateral compartments was analyzed by liquid scintilla-
tion counting. The percentage of [14C]erythromycin or
[3H]digoxin translocated to the receiving chamber was
calculated as the ratio of radioactivity measured in the
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receiving chamber to the sum of radioactivity measured
in the dosing and receiving chambers. Efflux ratios—
measures of net secretion—were calculated as the ratio
of the percentage of radiolabeled drug translocated into
the basolateral chamber to that translocated into the
apical chamber during the 4-hour period.
Statistical analysis
All statistical analyses were performed with use of
StatView (version 5.0.1; SAS Institute Inc, Cary, NC).
For the human subject study, nonparametric methods
were used because the data were not assumed to be
normally distributed. The Wilcoxon signed-rank test
was used to determine whether the effects of trolean-
domycin or rifampin treatment on the various ERMBT
and pharmacokinetic measurements were significantly
different from baseline (significance level of .05). Re-
lationships between the ERMBTIV and ERMBToral re-
sults and between each ERMBT result and erythromy-
cin CL/F or Cmax were assessed from the Spearman
correlation coefficient (rS), which was considered to be
significant if the P value was .05. For the cell culture
studies, the unpaired t test with equal variance was used
to determine whether a difference existed between
vehicle-treated and troleandomycin- or LY335979-
treated culture inserts (significance level of .05).
RESULTS
Intrasubject variation in the ERMBToral
A preliminary investigation was conducted in 15
healthy volunteers to evaluate the interday variability in
the ERMBToral within a subject. Fig 1 shows the test
result, expressed as the percentage of the dose oxidized
during the 0- to 3-hour breath collection interval, for
each subject on each of 3 days. Virtually identical
patterns ensued if the test result were based on the 1- to
3- or 2- to 3-hour collection interval (data not shown).
Within-subject variation was generally good (median,
19%; range, 9% to 105%). We therefore proceeded
with our evaluation of the ERMBToral in a separate
group of healthy volunteers. Our objective was to com-
pare the effects of the CYP3A4 modulators troleando-
mycin and rifampin on the ERMBTIV result, the
ERMBToral result, and on oral erythromycin pharma-
cokinetics.
ERMBTIV
In the current group of subjects (n 	 14), the median
ERMBTIV result at baseline was 1.85 and varied 3-fold
(range, 1.03-2.97; Fig 2, A). After troleandomycin ad-
ministration, the ERMBTIV result markedly decreased
in all subjects; the median test result was 0.09 (range,
0.05-0.22) and was significantly lower than that at
baseline (P 	 .001; Fig 2, A). After rifampin treatment,
the ERMBTIV result increased in all subjects, from 1.4-
to 5.7-fold above baseline (Fig 2, A). The median test
result significantly increased from baseline (to 4.23;
P 	 .001), and individual results ranged from 2.49 to
5.87.
ERMBToral
At baseline, the median (1.91) and range (0.63-2.66)
in the ERMBToral result, expressed as the percentage of
13CO2 exhaled during the 0- to 3-hour interval (Fig 2,
B), were comparable with those observed in our pre-
liminary investigation of 15 healthy subjects (Fig 1).
After troleandomycin administration, as with the
ERMBTIV result, the ERMBToral result decreased in all
subjects, and the median value (0.57; range, 0.00-0.83)
was significantly lower than that at baseline (P 	 .001;
Fig 2, B). After rifampin treatment, unlike with the
ERMBTIV result, the ERMBToral result increased
(1.3-fold above baseline) in only half of the subjects,
and no more than 1.7-fold (Fig 2, B). For the remaining
subjects, the oral test result was unchanged or was even
decreased (by as much as 90%) from baseline. Conse-
quently, the median ERMBToral result (1.97; range,
0.20-3.69) was not significantly different from that at
baseline (P 	 .30).
Oral erythromycin pharmacokinetics
Two representative plasma concentration versus time
profiles for erythromycin after administration of the
Fig 1. Intrasubject reproducibility in 15 healthy volunteers of
the result for the oral stable isotope (13C)-labeled formulation
of the erythromycin breath test, expressed as the percentage
of the erythromycin dose (500 mg) exhaled as 13CO2 over the
0- to 3-hour collection interval.
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ERMBToral for all 3 phases of the study are shown in
Fig 3, A and C, in which the rank order of AUC values
(troleandomycin 
 baseline 
 rifampin) was readily
apparent. Table I displays the median values and ranges
of the various pharmacokinetic measures (tmax, Cmax,
Z, and CL/F) determined for each phase of the study,
and those at baseline agreed with previous reports.21,22
The Cmax was generally achieved within 1.5 to 2.5
hours and, compared with baseline, the median tmax
was unchanged after troleandomycin (P 	 .19) and
rifampin (P 	 .37) treatment. Compared with baseline,
the median Cmax significantly increased with trolean-
domycin treatment (1.34 versus 2.92 mg/L; P 	 .001)
and significantly decreased with rifampin treatment (to
0.72 mg/L; P 	 .04). The median Z significantly
decreased from baseline with troleandomycin treatment
(0.35 versus 0.24 h1; P 	 .006) but remained un-
changed after rifampin treatment (0.38 h1; P 	 .70).
These values corresponded to terminal t1/2 values of 2.0
hours (baseline), 2.9 hours (troleandomycin), and 1.8
hours (rifampin). The percentage of total AUC extrap-
olated from 10 hours to infinite time was always
30%. The median erythromycin oral clearance dis-
played a pattern similar to the ERMBTIV result; that is,
CL/F decreased significantly (P 	 .001), by more than
70% compared with baseline, after troleandomycin ad-
ministration (96 versus 26 L/h) and significantly in-
creased (P 	 .013) after rifampin treatment (to 197
L/h). There was no change in the variability in eryth-
romycin CL/F when adjusted for body weight for all 3
phases of the study (data not shown).
Corresponding representative ERMBToral profiles
(percentage of 13C exhaled versus time) are presented
in Fig 3, B and D. For the subject shown in Fig 3, B, the
rank order of breath AUC values (rifampin 
 base-
line 
 troleandomycin) was opposite that for plasma
AUC values (Fig 3, A). This would be expected if the
reduction and elevation in erythromycin plasma levels
resulted solely from induction and inhibition, respec-
tively, of CYP3A4. For the subject shown in Fig 3, D,
however, the rank order of breath AUC values (base-
line 
 troleandomycin 
 rifampin) was not opposite
that for plasma AUC values (Fig 3, C). This paradoxic
scenario occurred in half of the 14 subjects.
Correlation analyses
Although the ERMBTIV and ERMBToral results
showed similar trends at baseline and with troleando-
mycin treatment, there was no rank-order correlation
between the 2 test results within either treatment group
(rS 	 0.47 and rS 	0.18, respectively; P .09). Not
surprisingly, there was no association between the 2
ERMBT results within the rifampin phase (rS 	
0.002; P 	 .99). There were no correlations between
erythromycin CL/F and either ERMBT result or be-
tween erythromycin Cmax and the ERMBTIV result
within each treatment group (P  .05). For the associ-
ation between erythromycin Cmax and the ERMBToral
result, there was a positive but insignificant trend at
baseline (rS 	 0.53; P 	 .06), no correlation with
troleandomycin treatment (rS 	 0.23; P 	 .41), and
a significant correlation with rifampin treatment (rS 	
0.64; P 	 .02; Fig 4).
Fig 2. Effects of troleandomycin (TAO) treatment (single
dose of 500 mg) and rifampin treatment (600 mg daily for 7
days) on the intravenous 14C-erythromycin breath test
(ERMBTIV) result (A) and the oral stable isotope (13C)-
labeled formulation of the erythromycin breath test
(ERMBToral) result (B) in 14 healthy volunteers. Open sym-
bols and broken lines denote median results.
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Troleandomycin is not an inhibitor of
erythromycin transport
To determine whether troleandomycin may have
confounded the interpretation of our in vivo results (by
altering erythromycin transport), we conducted an in
vitro experiment using [14C-N-methyl]erythromycin
and the human intestinal cell line Caco-2, which is
known to express P-glycoprotein (and other transport-
ers). As a positive control for P-glycoprotein activity,
an identical experiment was conducted with use of the
established P-glycoprotein probe substrate digoxin.23,24
For all culture inserts, at least 90% of the initial amount
of radioactivity added was recovered in the media col-
lected from the apical and basolateral chambers at the
end of the 4-hour incubation. Compared with vehicle-
treated culture inserts, troleandomycin had no effect on
the mean percentage of erythromycin translocated in
both the A3B direction (0.5% versus 0.5%; P 	 .34)
and B3A direction (48.9% versus 47.0%; P	 .20; Fig
5, A and B). In contrast, the selective P-glycoprotein
inhibitor LY335979 significantly increased mean
A3B translocation of erythromycin (to 6.4%; P 
.0001) and decreased mean B3A translocation of
erythromycin (to 12.5%; P  .0001; Fig 5, C). Simi-
larly, compared with vehicle-treated cultures, the aver-
age efflux ratio of erythromycin was unaffected by
troleandomycin (99.8 versus 87.9; P 	 .11) but was
significantly decreased by LY335979 (to 1.96; P 
.0001). Results with digoxin-treated cultures (Fig 5, D,
E, and F) were qualitatively identical to erythromycin-
treated cultures with statistically similar trends. Com-
pared with erythromycin, the mean B3A translocation
for digoxin was similar (43.4% and 44.6% for vehicle-
and troleandomycin-treated cultures, respectively),
whereas the mean A3B translocation was 5- to 7-fold
greater (3.4% and 2.5% for vehicle- and
Fig 3. Representative erythromycin plasma concentration–versus–time (A and C) and correspond-
ing 13CO2-labeled breath–versus–time (B and D) profiles. The rank-order area under the curve for
the breath test profile was either opposite (B) or not opposite (D) its plasma–time profile counterpart.
TAO, Troleandomycin.
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troleandomycin-treated cultures, respectively). Conse-
quently, the mean efflux ratio for digoxin was roughly
5-fold lower (15.5 and 19.5 for vehicle- and
troleandomycin-treated cultures, respectively) than that
for erythromycin. LY335979 inhibited both A3B and
B3A digoxin translocation so that the percentage of
the dose translocated in each direction was similar to
that for erythromycin (8.7% and 12.1% for A3B and
B3A, respectively), yielding an efflux ratio (1.44)
similar to that for erythromycin.
DISCUSSION
The overall goal of our study was to develop an oral
erythromycin breath test that was capable of assessing
aggregate liver and intestinal CYP3A4 activity. Anal-
ogous to the ERMBTIV, and with no diet restrictions,
the oral 13C-labeled formulation displayed good intra-
subject reproducibility for percentage of 13CO2 exhaled
in breath during the 0- to 3-hour interval after admin-
istration (Fig 1). The larger values for interday varia-
tion observed in the 2 subjects with the lowest values
(0.5%) were attributed to the greater sensitivity of
low values to the natural fluctuations in the ratio of 13C
to 12C in expired CO2, which can be influenced by food
and exercise.25 Accordingly, we proceeded with our
evaluation of this new test, which was to compare the
effects of prototypical CYP3A4 modulators on the
ERMBToral result, on the ERMBTIV result, and on oral
erythromycin disposition.
As expected, pretreatment with a single oral dose of
the CYP3A4 mechanism-based inhibitor troleandomy-
cin significantly decreased the median rate of labeled
CO2 production relative to baseline, regardless of the
route of erythromycin administration. Compared with
intravenous administration, the apparent weaker degree
of inhibition of erythromycin demethylation after oral
administration (95% versus 70%) may have arisen from
the time course of troleandomycin inhibition. With the
ERMBTIV, a single breath sample was collected 20
minutes after injection, or 2 hours and 20 minutes after
troleandomycin was given. With the ERMBToral,
breath samples were continually collected until 3 hours
after drug administration, or 5 hours after troleandomy-
cin was given. With the ERMBTIV we have found that
inhibition of CYP3A4 by a single oral dose of trolean-
domycin peaks between 2 and 3 hours, then wanes
thereafter (unpublished observations). The reduced
magnitude of inhibition observed with the ERMBToral
may therefore simply have reflected a “wearing off” of
the troleandomycin effect. As with the ERMBTs, trole-
andomycin treatment significantly decreased the me-
dian CL/F of erythromycin (to less than one third of
that at baseline), consistent with the premise that trole-
andomycin interacts with erythromycin by inhibition of
CYP3A4, which could occur in the intestine or liver.
Rifampin treatment doubled the median rate of
14CO2 exhaled from the ERMBTIV, which was antici-
pated because rifampin is a well-established and potent
inducer of CYP3A4. Likewise, the median CL/F of
erythromycin doubled and, together with the ERMBTIV
result, was consistent with hepatic CYP3A4 induction
as a mechanism that underlies the oral erythromycin-
rifampin interaction. Unlike troleandomycin, however,
rifampin did not alter the median production of 13CO2
from the ERMBToral. That is, in spite of a marked
interaction between rifampin and oral erythromycin,
the total demethylation of erythromycin unexpectedly
appeared to be unchanged relative to baseline. One
explanation is that rifampin treatment indeed resulted in
increased erythromycin N-demethylation in the intes-
tine, but this was not reflected in increased production
of breath 13CO2. This could occur if the 13C-labeled
formaldehyde generated in the intestine did not undergo
the same fate (in terms of one carbon pool kinetics) as
Table I. Pharmacokinetics of erythromycin (500 mg) after oral administration to 14 healthy volunteers
Study phase Cmax (mg/L) tmax (h) Z (h1) CL/F (L/h)
Baseline
Median 1.34 1.5 0.35 96
Range 0.40-3.16 0.5-5.0 0.21-0.45 37-250
Troleandomycin
Median 2.92* 2.0 0.24* 26*
Range 0.95-4.80 1.0-5.0 0.15-0.38 17-73
Rifampin (INN, rifampicin)
Median 0.72* 2.5 0.38 197*
Range 0.06-1.66 1.0-5.0 0.14-0.51 102-2015
Cmax, Maximum plasma concentration; tmax, time to reach Cmax; Z, terminal elimination rate constant; CL/F, apparent oral clearance.
*Statistically different from baseline (P  .05; Wilcoxon signed-rank test).
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formaldehyde generated in the liver. This seems to be
unlikely, however, because the enzymes involved in
one carbon pool kinetics are believed to be ubiquitous.
Another unforeseen finding was the positive associ-
ation between erythromycin Cmax and the ERMBToral
result at baseline and with rifampin treatment (Fig 4). If
erythromycin Cmax were assumed to be largely a re-
flection of first-pass metabolism, an association be-
tween a high rate of 13CO2 production and a low Cmax
would be expected. However, the opposite trend oc-
curred (a high rate of 13CO2 production was associated
with a high Cmax), indicating that CYP3A4-mediated
first-pass metabolism (in the intestine or liver) is not the
major determinant of erythromycin Cmax, particularly
during rifampin treatment. Collectively, the lack of
effect of rifampin on the median rate of erythromycin
demethylation (as indicated by the ERMBToral) and the
positive association between erythromycin Cmax and
the ERMBToral result strongly imply that a mecha-
nism(s) in addition to CYP3A4 induction must account
for the oral erythromycin-rifampin interaction. One
plausible mechanism may involve the transmembrane
secretory pump P-glycoprotein.
P-glycoprotein, the product of the multidrug resis-
tance gene MDR1, is an apically directed and adenosine
triphosphate–dependent transporter that was first iden-
tified in human cancer cells; it acts to extrude certain
chemotherapeutic agents from the cell and to render the
agent ineffective.26 P-glycoprotein has also been de-
tected in normal human tissues, including capillary
endothelial cells of the brain, epithelial cells (brush
border) of the renal tubule and intestine, and the cana-
licular membrane of hepatocytes.26,27 Because of its
luminal-canalicular location in these tissues,
P-glycoprotein functions to limit brain uptake, to re-
duce absorption, and to enhance the renal, intestinal,
and biliary excretion of its substrates (reviewed by
Ambudkar et al26). Along with numerous other drugs
and xenobiotics, erythromycin has been shown to be a
substrate for P-glycoprotein, and a pronounced role for
this efflux pump in erythromycin disposition in vivo in
rats has been reported.28
In humans, rifampin is an inducer not only of intes-
tinal (and hepatic) CYP3A4 but also of intestinal
P-glycoprotein.24,29 Although not confirmed by direct
intestinal biopsy measurements in this study, we can
assume that rifampin treatment induced both proteins.
Consequently, the reduction in oral erythromycin AUC
by rifampin was likely largely the result of an increase
in intestinal P-glycoprotein levels. The lack of effect of
rifampin on the median ERMBToral result could there-
fore be explained if induction of P-glycoprotein re-
sulted in roughly a 50% decrease in the median amount
of erythromycin absorbed from the gut lumen. This
alone would explain why the median AUC value of
erythromycin after rifampin administration was ap-
proximately half of the median erythromycin AUC at
baseline (2.5 versus 5.2 mg  h/L). A 2-fold induction in
CYP3A4 activity (as reflected in the 2-fold increase in
the median ERMBTIV result) would therefore explain
why the median ERMBToral result was similar to that
observed at baseline. In other words, the median rate of
13CO2 expired from the ERMBToral remained un-
Fig 4. Spearman rank correlation between the ERMBToral
result and plasma erythromycin maximum plasma concentra-
tion (Cmax) at baseline after troleandomycin (TAO) treatment
(single dose of 500 mg) and after rifampin treatment (600 mg
daily for 7 days) in 14 healthy subjects.
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changed after rifampin treatment because CYP3A4 in-
duction (in the intestine and liver) was offset by the
reduced delivery of erythromycin to the enzyme (be-
cause of reduced absorption).
P-glycoprotein in organs other than the intestine (eg,
kidney, brain, and liver) may have also influenced
erythromycin disposition. However, the percentage of
an oral erythromycin dose excreted unchanged in the
urine (2% to 5%)30 is minimal, making a role for renal
P-glycoprotein unlikely. Although erythromycin is not
detected in normal cerebrospinal fluid and brain tis-
sue,30 perhaps suggesting a role for cerebral
P-glycoprotein, it seems to be intuitively unlikely that
P-glycoprotein in the central nervous system would
have a major impact on erythromycin disposition. A
role for hepatic P-glycoprotein, however, cannot be
ruled out. When mdr1a nullizygous (/) and
mdr1a/1b (/) mice received an intravenous injec-
tion of [14C-N-methyl]erythromycin, the breath 14CO2
AUC was 1.5- and 1.9-fold greater, respectively, com-
pared with that for the wild-type counterparts, despite
having equivalent levels of hepatic CYP3A4.31 These
observations raised the possibility that hepatic
P-glycoprotein influenced CYP3A4-mediated metabo-
lism. Although induction of hepatic P-glycoprotein by
rifampin may have occurred and may have influenced
the current observations, it would be expected that such
induction would have comparable effects on both the
oral and ERMBTIV results. Hepatic P-glycoprotein
therefore would not account for the discrepancy be-
tween the ERMBToral and ERMBTIV results.
Troleandomycin did not alter the transport of eryth-
romycin or of the P-glycoprotein substrate digoxin in
monolayers of the human intestinal cell line Caco-2,
suggesting that the effects observed in vivo with trole-
andomycin pretreatment were the result of selective
CYP3A4 inhibition. We therefore concluded that
CYP3A4-mediated metabolism represents a major
pathway for the elimination of erythromycin in unin-
duced individuals. The lack of effect of troleandomycin
Fig 5. Apical-to-basolateral (A to B) and basolateral-to-apical (B to A) translocation of [14C]-
erythromycin (10 mol/L, 0.5 Ci; A, B, and C) and [3H]digoxin (5 mol/L, 1 Ci; D, E, and F)
in Caco-2 cell monolayers. Cell monolayers were incubated with vehicle (A and D), the CYP3A4
inhibitor troleandomycin (30 mol/L; B and E), or the selective P-glycoprotein inhibitor LY335979
(0.5 mol/L; C and F) alone for 30 minutes and then with erythromycin (ERM) or digoxin (DIG)
plus vehicle or inhibitor for 4 hours. Symbols and error bars denote mean values and standard
deviations, respectively, of triplicate culture inserts.
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on P-glycoprotein activity also explained why the
changes in the ERMBTIV result, the ERMBToral result,
and the various oral erythromycin pharmacokinetic
measurements were the same as the predicted changes.
Rivory et al32 recently reported that the ERMBTIV
result did not correlate with the systemic clearance of
erythromycin in 16 adult patients with cancer. Al-
though we did not directly assess the systemic clear-
ance of erythromycin in this study, it is interesting that
the median Z of erythromycin was only modestly
reduced after CYP3A4 inhibition (by troleandomycin)
and was unaffected after CYP3A4 induction (by ri-
fampin; Table I). Assuming that the 2 modulators of
CYP3A4 did not alter the (terminal) volume of distri-
bution of erythromycin, these observations support the
contention that CYP3A4-mediated metabolism is not
rate limiting in the systemic clearance of erythromycin.
It should be noted that the contribution of other non–
CYP3A4-mediated pathways in the systemic clearance
of erythromycin would not invalidate the ERMBTIV as
a measure of hepatic CYP3A4 activity, unless such
pathways significantly altered the hepatic concentration
of erythromycin 20 minutes after injection (ie, when the
single breath sample is collected).33
In conclusion, because the oral erythromycin breath
test does not appear to simply reflect aggregate intes-
tinal and hepatic CYP3A4 activity, this test would not
be suitable as an in vivo CYP3A4 phenotyping probe.
However, a key finding during the course of the eval-
uation of this test was that the oral erythromycin-
rifampin interaction was not solely the result of
CYP3A4 induction and likely also reflected intestinal
P-glycoprotein induction. This would not have surfaced
if we had examined only erythromycin pharmacokinet-
ics. To our knowledge, the erythromycin-rifampin in-
teraction represents the first example in which
P-glycoprotein appears to be a major locus for an
interaction that involves a substrate administered in
half-gram quantities. It therefore seems that
P-glycoprotein can serve as a relatively high-capacity
xenobiotic transporter in vivo. Although erythromycin
and rifampin are rarely prescribed together, results
from this study may well apply to drug-rifampin inter-
actions that involve other CYP3A4 and P-glycoprotein
substrates similarly given in large quantities (eg, the
human immunodeficiency virus protease inhibitors sa-
quinavir, indinavir, and amprenavir). What may appear
to be consistent with CYP3A4-mediated metabolism
may also reflect P-glycoprotein-mediated efflux.
We thank Dr Paul Stewart, Department of Biostatistics, for his
helpful advice with the statistical analyses and Mrs Anne Criss for her
excellent technical assistance with the Caco-2 cell studies.
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